Q-omics provides the consensus-scored CLCN7 profile across patient tissues and cancer cell-line models. CLCN7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLCN7 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CLCN7 protein abundance shows 23,671 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where CLCN7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLCN7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLCN7 survival associations across molecular data types. CLCN7 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLCN7 RNA expression–survival associations across cancer types. High CLCN7 expression shows unfavorable associations in KIRC, LUSC and LGG, but favorable associations in HNSC, BRCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLCN7 RNA expression.
This table summarizes CLCN7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CLCN7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLCN7 shows higher tumor expression in HNSC, COAD, KIRP, LIHC, STAD and BRCA. The HNSC box plot shows higher CLCN7 RNA expression in tumor versus normal tissue (log2 FC = +1.043, t-test p < 0.001).
This table shows molecular features associated with CLCN7 in patient tissues and cancer cell lines. In patient samples, CLCN7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLCN7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
